Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus’s Zegerid capsules found effective against GERD
The primary endpoint of the open-label, randomized, crossover study was to evaluate the effects of morning dosing of Zegerid capsules, Protonix tablets and Prevacid capsules on 24-hour gastric
The primary endpoint of the open-label, randomized, crossover study was to evaluate the effects of morning dosing of Zegerid capsules, Protonix tablets and Prevacid capsules on 24-hour gastric
Through the definitive license agreement Taisho will grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. Under the agreement, Taisho will receive from Pfizer an
The Spinal Cord Injury Project is the first focus of the W M Keck Center for Collaborative Neuroscience at Rutgers University. The study, combined with BrainStorm’s unique differentiation
The notes will be convertible, in certain circumstances, into common stock of OSI based upon a base conversion rate, which, under certain circumstances will be increased pursuant to
This study was a multi-center, double-blind, parallel-group, randomized, placebo-controlled trial in 381 adults ages 21 to 64 with co-morbid chronic insomnia and GAD. The study evaluated the overall
The four-year grant, which is part of the Foundation’s LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative, was awarded to Alnylam, Mayo Clinic of Jacksonville, Florida, and the
For the planned series of Phase II multi-centered, controlled clinical trials to be performed in the US, Innocoll has appointed Premier Research Group to co-ordinate up to five
MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and survival, blood vessel formation (angiogenesis)
Interwest Partners led the financing and existing investors PureTech Ventures participated. The funding is expected to take the company through a clinical proof of concept study. Rox Anderson,
The sale coincides with the closing of the amended merger agreement with Advanced Bionics announced on August 9, 2007. As part of a new schedule of consolidated, fixed